Bitcoin price today: dips below $109k as recovery stalls, "Uptober" cheer fizzles
Investing.com - UBS maintained its buy rating and $40.00 price target on Option Care Health (NASDAQ:OPCH) stock on Tuesday amid investor concerns about potential impacts from UnitedHealth Group (NYSE:UNH)’s elevated medical costs. For deeper insights into OPCH’s valuation metrics and financial health indicators, check out InvestingPro.
UnitedHealth represents Option Care Health’s only payer accounting for more than 10% of total revenues, prompting questions about possible implications for the home infusion provider as UnitedHealth faces medical cost challenges.
Option Care Health does not expect UnitedHealth’s issues to negatively affect its outlook, according to UBS. Instead, the company sees an opportunity to demonstrate its value proposition to health plans.
The company believes it can help insurers reduce total cost of care for patients by providing services in one of the lowest-cost care settings. Option Care Health positions itself as one of the only scaled national providers for acute therapies.
Management indicated the situation is leading to more productive discussions with payers about the value Option Care Health provides, though it does not anticipate a massive shift or impact from a payer perspective.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.